Amgen Announces Phase 2 MariTide Study Results Showing Promising Weight Loss for Obesity and Type 2 Diabetes at ADA Scientific Sessions

Reuters
Jun 18
Amgen Announces Phase 2 MariTide Study Results Showing Promising Weight Loss for Obesity and Type 2 Diabetes at ADA Scientific Sessions

Amgen Inc. has announced that it will present the full results from Part 1 of the Phase 2 study for its investigational drug, MariTide (maridebart cafraglutide), at the upcoming 85th American Diabetes Association $(ADA.AU)$ Scientific Sessions. The presentation will occur on June 23, 2025, in Chicago. MariTide is being investigated as a treatment for obesity and Type 2 diabetes, and it is noted for being the first monthly or less frequently dosed peptide-antibody conjugate for these conditions. The study results, which have been pivotal for the design of the Phase 3 MARITIME program, show significant weight loss over 52 weeks without a plateau in participants with obesity, both with and without Type 2 diabetes. Additionally, Amgen will host an investor webcast on June 23, 2025, at 4:30 p.m. CDT to discuss the MariTide data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA13090) on June 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10